Physician profile
Allyson J Smith
NPI 1700360286
$6,462.22
in general payments reported to CMS, 2019-2025
35 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,545 · 2022: $1,204 · 2023: $957 · 2024: $1,660 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,088.12 | 2021 | |
| Novo Nordisk INC | $851.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $643.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $617.76 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $593.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $492.40 | 2022-2024 | |
| Glaxosmithkline, LLC. | $439.90 | 2021-2025 | Arexvy, Shingrix, Bexsero |
| Abbott Laboratories | $252.51 | 2024-2025 | Freestyle Libre, Freestyle Libre 3 |
| Exact Sciences Corporation | $219.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $174.58 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $150.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.81 | 2021-2024 | Jardiance |
| Sanofi Pasteur INC. | $73.26 | 2021-2025 | |
| Astellas Pharma US INC | $73.17 | 2023-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $69.65 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.93 | 2023-2024 | Dificid, Gardasil 9, Gardasil |
| Alk-Abello, INC | $61.00 | 2025 | Neffy, Grastek, Odactra |
| Idorsia Pharmaceuticals US INC | $56.95 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $50.18 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $49.39 | 2023 | Xarelto |
| Althera Pharmaceuticals LLC | $44.84 | 2021-2022 | |
| Medtronic, INC. | $31.55 | 2023-2024 | Venaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $29.62 | 2021 | |
| Corium, LLC | $28.89 | 2023 | Azstarys |
| Jazz Pharmaceuticals INC. | $24.07 | 2021 | |
| Sobi, INC | $23.16 | 2021 | |
| Inspire Medical Systems, INC. | $19.33 | 2023 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $15.83 | 2023 | Eliquis |
| Lundbeck LLC | $14.19 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.27 | 2021 | |
| Amarin Pharma, INC. | $12.75 | 2022 | |
| Neos Therapeutics, LP | $12.28 | 2022 | |
| Optinose US, INC. | $12.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2021 | |
| Genentech USA, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.